International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1293-1295 , 1 August 2010

Molecular Subtyping of Early-Stage Breast Cancer: Implications for Radiation Therapy

  • Bruce G. Haffty, M.D.

      Affiliations

    • Department of Radiation Oncology, UMDNJ/Robert Wood Johnson Medical School & The Cancer Institute of New Jersey, New Brunswick, NJ
    • Corresponding Author InformationReprint requests to: Bruce G. Haffty, M.D., Department of Radiation Oncology, UMDNJ-RWJMS, Cancer Institute of New Jersey, 195 Little Albany St., New Brunswick, NJ 08901. Tel: (732) 235-5203; Fax: (732) 235-7493
    • ,
  • Sharad Goyal, M.D.

      Affiliations

    • Department of Radiation Oncology, UMDNJ/Robert Wood Johnson Medical School & The Cancer Institute of New Jersey, New Brunswick, NJ

Received 20 January 2010 ,Accepted 2 February 2010.

References 

  1. Haffty BG. Molecular and genetic markers in the local-regional management of breast cancer. Semin Radiat Oncol. 2002;12:329–340
  2. Freedman GM, Anderson PR, Li T, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation. Cancer. 2009;115:946–951
  3. Haffty BG, Brown F, Carter D, et al. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study. Int J Radiat Oncol Biol Phys. 1996;35:751–757
  4. Haffty BG, Glazer PM. Molecular markers in clinical radiation oncology. Oncogene. 2003;22:5915–5925
  5. Haffty BG, Yang Q, Moran MS, et al. Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys. 2008;71:1006–1013
  6. Santiago RJ, Wu L, Harris E, et al. Fifteen-year results of breast-conserving surgery and definitive irradiation for Stage I and II breast carcinoma: The University of Pennsylvania experience. Int J Radiat Oncol Biol Phys. 2004;58:233–240
  7. Yang Q, Moran MS, Haffty BG. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res Treat. 2009;115:343–348
  8. Zellars RC, Hilsenbeck SG, Clark GM, et al. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol. 2000;18:1906–1913
  9. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24(36):5652–5657
  10. Nguyen PL, Taghian AG, Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–2378
  11. Cheng SH, Horng CF, West M, et al. Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol. 2006;24:4594–4602
  12. Nuyten DS, Kreike B, Hart AA, et al. Predicting a local recurrence after breast-conserving therapy by gene expression profiling. Breast Cancer Res. 2006;8:R62
  13. Kreike B, Halfwerk H, Kristel P, et al. Gene expression profiles of primary breast carcinomas from patients at high risk for local recurrence after breast-conserving therapy. Clin Cancer Res. 2006;12:5705–5712
  14. Kreike B, Halfwerk H, Armstrong N, et al. Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res. 2009;15:4181–4190
  15. Mamounas E. J Clin Oncol. 2010;28(10):1677–1683
  16. Mamounas EP, Tang G, Fisher B, et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. J Clin Oncol. 2010;28:1677–1683
  17. Buchholz TA, Tucker SL, Erwin J, et al. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy. J Clin Oncol. 2001;19:2240–2246
  18. Haffty BG, Wilmarth L, Wilson L, et al. Adjuvant systemic chemotherapy and hormonal therapy. Effect on local recurrence in the conservatively treated breast cancer patient. Cancer. 1994;73:2543–2548
  19. Jobsen JJ, van der Palen J, Ong F, et al. The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radiat Oncol Biol Phys. 2003;57:724–731
  20. Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: Influence of margin status and systemic therapy on local recurrence. J Clin Oncol. 2000;18:1668–1675
  21. van der Leest M, Evers L, van der Sangen MJ, et al. The safety of breast-conserving therapy in patients with breast cancer aged < or = 40 years. Cancer. 2007;109:1957–1964
  22. Albert JE, Gonzalez-Angulo AM, Guray M, et al. Estrogen/progesterone receptor negativity and HER2 positivity predict locoregional recurrence in patients with T1a, bN0 breast cancer. Int J Radiat Oncol Biol Phys. 2010;In press.
  23. Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007;25:3259–3265
  24. Jones HA, Antonini N, Hart AA, et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: A subgroup analysis of the EORTC boost versus no boost trial. J Clin Oncol. 2009;27:4939–4947
  25. Poortmans PM, Collette L, Horiot JC, et al. Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. Radiother Oncol. 2009;90:80–85
  26. Fisher B, Bryant J, Dignam JJ, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20:4141–4149
  27. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–1684

 Conflict of interest: None.

PII: S0360-3016(10)00423-2

doi: 10.1016/j.ijrobp.2010.03.017

International Journal of Radiation Oncology * Biology * Physics
Volume 77, Issue 5 , Pages 1293-1295 , 1 August 2010

Article Tools